Eva Hellström Lindberg

About me
Publications
CV
Public outreach and news

About me

I am double specialist in hematology and internal medicine since 1993 and Professor of hematology at the Department of Medicine, Huddinge since 2009. I have worked within the translational research field for many years and been actively involved in strategic research questions. I have been president for the European Association of Hematology and for the Swedish Society of Hematology.

I am leading the Eva Hellström-Lindberg group – Myelodysplastic syndromes, at the Deparment of Medicine, Huddinge.

Education
I was previously involved in graduate training within ethics and communication skills. Presently I am focused on creating a good environment for post graduate students. I was previously Chair for doctoral studies at the Department of Medicine Huddinge for five years.

Academic honours, awards and prizes
I have received both junior and senior research awards from the Swedish Cancer Society.
In 2018 I received a Wallenberg Clinical Scholar grant
3 million per year for 5 years.
In 2016, I received José Carreras Award: This year's premier hematological award in Europe.

Research

My research program focuses on the hemopoietic stem cell malignancy myelodysplastic syndromes (MDS) and include genetic, epigenetic, and cellular studies.

The aim is to understand mechanisms for disease progression, leukemic transformation, and erythroid failure. I also lead a clinical specialist program for patients with this disease, as well as the Nordic MDS research group, which drives a broad clinical trial and biomarker program.

Furthermore, I am Chair for the Center for Hematology and Regenerative Medicine at Campus Flemingsberg, a translational research environment combining basic and clinical competences within hematology, regenerative medicine and immunology.

Selected publications

Article: SEMINARS IN HEMATOLOGY. 2022;59(3):150-155
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?
Todisco G; Moura PL; Hellstrom-Lindberg E
Article: NATURE MEDICINE. 2020;26(10):1549-1556
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Article: BLOOD. 2020;136(2):157-170
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tuechler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
Article: LEUKEMIA. 2020;34(1):271-282
A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
Elvarsdottir EM; Mortera-Blanco T; Dimitriou M; Bouderlique T; Jansson M; Hofman IJF; Conte S; Karimi M; Sander B; Douagi I; Woll PS; Hellstrom-Lindberg E
Article: LEUKEMIA. 2019;33(2):522-527
Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes
Ryden J; Edgren G; Karimi M; Walldin G; Tobiasson M; Wikman A; Hellstrom-Lindberg E; Hoglund P
Article: NATURE COMMUNICATIONS. 2018;9(1):3649
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia
Shiozawa Y; Malcovati L; Galli A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellstrom-Lindberg E; Miyano S; Ogawa S; Cazzola M
Article: CELL. 2018;173(5):1204-1216.e26
Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells
Guzzi N; Ciesla M; Phuong CTN; Lang S; Arora S; Dimitriou M; Pimkova K; Sommarin MNE; Munita R; Lubas M; Lim Y; Okuyama K; Soneji S; Karlsson G; Hansson J; Jonsson G; Lund AH; Sigvardsson M; Hellstrom-Lindberg E; Hsieh AC; Bellodi C
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;180(4):526-533
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment
Scharenberg C; Jansson M; Saft L; Hellstrom-Lindberg E
Article: BLOOD. 2017;130(24):2642-2653
Gene expression and risk of leukemic transformation in myelodysplasia
Shiozawa Y; Malcovati L; Galli A; Pellagatti A; Karimi M; Sato-Otsubo A; Sato Y; Suzuki H; Yoshizato T; Yoshida K; Shiraishi Y; Chiba K; Makishima H; Boultwood J; Hellstrom-Lindberg E; Miyano S; Cazzola M; Ogawa S
Article: BLOOD. 2017;130(7):881-890
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellstrom-Lindberg E
Article: ONCOTARGET. 2017;8(17):28812-28825
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grovdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Article: ONCOTARGET. 2016;7(45):72685-72698
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality
Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SEW; Hellstrom-Lindberg E

Articles

Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(12):1378-1390
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Lundstrom LY; von Bahr L; Baltzer-Sollander K; Jadersten M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellstrom-Lindberg E
Article: BLOOD. 2024;143(11):953-966
Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation
Dimitriou M; Mortera-Blanco T; Tobiasson M; Mazzi S; Lehander M; Hoegstrand K; Karimi M; Walldin G; Jansson M; Vonlanthen S; Ljungman P; Langemeijer S; Yoshizato T; Hellstroem-Lindberg E; Woll PS; Jacobsen SEW
Article: CANCER RESEARCH COMMUNICATIONS. 2024;4(2):365-377
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roue G; Valcarcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellstrom-Lindberg E; Sole F; Esteller M
Article: CANCER RESEARCH. 2024;84(2):211-225
Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Bjoerklund A-C; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellstrom-Lindberg E
Article: LEUKEMIA RESEARCH. 2023;134:107386
MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients
Larfors G; Berggren DM; Garelius H; Nilsson L; Rasmussen B; Hellstrom-Lindberg E; Ejerblad E
Article: GENES CHROMOSOMES AND CANCER. 2023;62(11):672-677
The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression
Granados DC; Barbosa I; Baliakas P; Hellstrom-Lindberg E; Lundin V
Article: TRANSFUSION. 2023;63(11):2040-2051
Red blood cell alloimmunization in myelodysplastic syndromes: Associations with sex, DAT-positivity, and increased transfusion needs
Ryden J; Clements M; Wikman A; Hellstrom-Lindberg E; Edgren G; Hoglund P
Article: CLINICAL CANCER RESEARCH. 2023;29(20):4256-4267
Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
Todisco G; Creignou M; Bernard E; Bjorklund A-C; Moura PL; Tesi B; Mortera-Blanco T; Sander B; Jansson M; Walldin G; Barbosa I; Reinsbach SE; Hofman IJ; Nilsson C; Yoshizato T; Dimitriou M; Chang D; Olafsdottir S; Larsson SV; Tobiasson M; Malcovati L; Woll P; Jacobsen SEW; Papaemmanuil E; Hellstroem-Lindberg E
Article: BLOOD ADVANCES. 2023;7(14):3624-3636
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellstrom-Lindberg E; Ogawa S
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: BLOOD. 2023;141(23):2853-2866
The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia
Hakkarainen M; Kaaja I; Douglas SPM; Vulliamy T; Dokal I; Soulier J; Larcher L; de Latour RP; Leblanc T; de Fontbrune FS; Siitonen T; Lohi O; Hellstrom-Lindberg E; Barbany G; Tesi B; Shimamura A; Beier F; Jackson S; Kuperman AA; Zaccai TF; Tamary H; Mecucci C; Capolsini I; Jahnukainen K; Salmenniemi U; Niinimaki R; Varilo T; Kilpivaara O; Wartiovaara-Kautto U
Article: LEUKEMIA. 2023;37(5):1103-1112
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective
Berggren DM; Garelius H; Hjelm PW; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: BLOOD. 2023;141(17):2047-2061
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Zeidan AM; Platzbecker U; Bewersdorf JP; Stahl M; Ades L; Borate U; Bowen D; Buckstein R; Brunner A; Carraway HE; Daver N; Diez-Campelo M; de Witte T; DeZern AE; Efficace F; Garcia-Manero G; Garcia JS; Germing U; Giagounidis A; Griffiths EA; Hasserjian RP; Hellstrom-Lindberg E; Iastrebner M; Komrokji R; Kulasekararaj AG; Malcovati L; Miyazaki Y; Odenike O; Santini V; Sanz G; Scheinberg P; Stauder R; van de Loosdrecht AA; Wei AH; Sekeres MA; Fenaux P
Article: MOLECULAR CELL. 2023;83(7):1165-1179.e11
m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis
Ciesla M; Ngoc PCT; Muthukumar S; Todisco G; Madej M; Fritz H; Dimitriou M; Incarnato D; Hellstrom-Lindberg E; Bellodi C
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2023;200(4):451-461
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry
Madry K; Lis K; Fenaux P; Bowen D; Symeonidis A; Mittelman M; Stauder R; Cermak J; Sanz G; Hellstrom-Lindberg E; Langemeijer S; Malcovati L; Germing U; Holm MS; Guerci-Bresler A; Culligan D; Sanhes L; Kotsianidis I; van Marrewijk C; Crouch S; de Witte T; Smith A
Article: BLOOD. 2022;140(21):2228-2247
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage EJ; Bagg A; Hasserjian RP; DiNardo CD; Godley LA; Iacobucci I; Jaiswal S; Malcovati L; Vannucchi AM; Patel KP; Arber DA; Arcila ME; Bejar R; Berliner N; Borowitz MJ; Branford S; Brown AL; Cargo CA; Dohner H; Falini B; Garcia-Manero G; Haferlach T; Hellstrom-Lindberg E; Kim AS; Klco JM; Komrokji R; Loh ML-C; Loghavi S; Mullighan CG; Ogawa S; Orazi A; Papaemmanuil E; Reiter A; Ross DM; Savona M; Shimamura A; Skoda RC; Sole F; Stone RM; Tefferi A; Walter MJ; Wu D; Ebert BL; Cazzola M
Article: BLOOD. 2022;140(11):1200-1228
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber DA; Orazi A; Hasserjian RP; Borowitz MJ; Calvo KR; Kvasnicka H-M; Wang SA; Bagg A; Barbui T; Branford S; Bueso-Ramos CE; Cortes JE; Dal Cin P; DiNardo CD; Dombret H; Duncavage EJ; Ebert BL; Estey EH; Facchetti F; Foucar K; Gangat N; Gianelli U; Godley LA; Gokbuget N; Gotlib J; Hellstrom-Lindberg E; Hobbs GS; Hoffman R; Jabbour EJ; Kiladjian J-J; Larson RA; Le Beau MM; Loh ML-C; Lowenberg B; Macintyre E; Malcovati L; Mullighan CG; Niemeyer C; Odenike OM; Ogawa S; Orfao A; Papaemmanuil E; Passamonti F; Porkka K; Pui C-H; Radich JP; Reiter A; Rozman M; Rudelius M; Savona MR; Schiffer CA; Schmitt-Graeff A; Shimamura A; Sierra J; Stock WA; Stone RM; Tallman MS; Thiele J; Tien H-F; Tzankov A; Vannucchi AM; Vyas P; Wei AH; Weinberg OK; Wierzbowska A; Cazzola M; Dohner H; Tefferi A
Article: LEUKEMIA. 2022;36(9):2317-2327
Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia
Kelkka T; Tyster M; Lundgren S; Feng X; Kerr C; Hosokawa K; Huuhtanen J; Keranen M; Patel B; Kawakami T; Maeda Y; Nieminen O; Kasanen T; Aronen P; Yadav B; Rajala H; Nakazawa H; Jaatinen T; Hellstrom-Lindberg E; Ogawa S; Ishida F; Nishikawa H; Nakao S; Maciejewski J; Young NS; Mustjoki S
Article: LEUKEMIA AND LYMPHOMA. 2022;63(10):2311-2320
Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium
Engvall M; Karlsson Y; Kuchinskaya E; Jornegren A; Mathot L; Pandzic T; Palle J; Ljungstrom V; Cavelier L; Lindberg EH; Cammenga J; Baliakas P
Article: NEJM EVID. 2022;1(7):evidoa2200008
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
Article: BLOOD ADVANCES. 2022;6(10):2992-3005
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
Asimomitis G; G. Deslaurnes A; Kotini AG; Bernard E; Esposito D; Olszewska M; Spyrou N; Ossa JA; Mortera-Blanco T; Koche R; Malcovati L; Ogawa S; Cazzola M; Aaronson SA; Hellstro-Lindberg E; Papaemmanuil E; Nannya Y; Papapetrou EP
Article: NATURE CELL BIOLOGY. 2022;24(3):299-306
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
Guzzi N; Muthukumar S; Ciesla M; Todisco G; Ngoc PCT; Madej M; Munita R; Fazio S; Ekstrom S; Mortera-Blanco T; Jansson M; Nannya Y; Cazzola M; Ogawa S; Malcovati L; Hellstrom-Lindberg E; Dimitriou M; Bellodi C
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jadersten M; Hellstrom-Lindberg E; Gronbaek K; Ljungman P; Friis LS
Article: BLOOD CANCER DISCOVERY. 2021;2(5):500-517
ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing
Beauchamp EM; Leventhal M; Bernard E; Hoppe ER; Todisco G; Creignou M; Galli A; Castellano CA; McConkey M; Tarun A; Wong W; Schenone M; Stanclift C; Tanenbaum B; Malolepsza E; Nilsson B; Bick AG; Weinstock JS; Miller M; Niroula A; Dunford A; Taylor-Weiner A; Wood T; Barbera A; Anand S; Psaty BM; Desai P; Cho MH; Johnson AD; Loos R; MacArthur DG; Lek M; Neuberg DS; Lage K; Carr SA; Hellstrom-Lindberg E; Malcovati L; Papaemmanuil E; Stewart C; Getz G; Bradley RK; Jaiswal S; Ebert BL
Article: BLOOD ADVANCES. 2021;5(16):3066-3075
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS
Oster HS; Crouch S; Smith A; Yu G; Abu Shrkihe B; Baruch S; Kolomansky A; Ben-Ezra J; Naor S; Fenaux P; Symeonidis A; Stauder R; Cermak J; Sanz G; Hellstrom-Lindberg E; Malcovati L; Langemeijer S; Germing U; Holm MS; Madry K; Guerci-Bresler A; Culligan D; Sanhes L; Mills J; Kotsianidis I; van Marrewijk C; Bowen D; de Witte T; Mittelman M
Article: LEUKEMIA. 2021;35(8):2371-2381
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2^P95-mutated neoplasms
Todisco G; Creignou M; Gall A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catrical S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellstrom-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Article: LEUKEMIA. 2021;35(6):1745-1750
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Hoeks M; Bagguley T; van Marrewijk C; Smith A; Bowen D; Culligan D; Kolade S; Symeonidis A; Garelius H; Spanoudakis M; Langemeijer S; Roelofs R; Wiegerinck E; Tatic A; Killick S; Panagiotidis P; Stanca O; Hellstrom-Lindberg E; Cermak J; van der Klauw M; Wouters H; van Kraaij M; Blijlevens N; Swinkels DW; de Witte T
Article: LEUKEMIA. 2021;35(5):1365-1379
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia
Lundgren S; Keranen MAI; Kankainen M; Huuhtanen J; Walldin G; Kerr CM; Clemente M; Ebeling F; Rajala H; Bruck O; Lahdesmaki H; Hannula S; Hannunen T; Ellonen P; Young NS; Ogawa S; Maciejewski JP; Hellstrom-Lindberg E; Mustjoki S
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2021;23(3):347-357
Multicenter Next-Generation Sequencing Studies between Theory and Practice Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data
Sandmann S; de Graaf AO; Tobiasson M; Kosmider O; Abaigar M; Clappier E; Galli A; van der Reijden BA; Malcovati L; Fenaux P; Diez-Campelo M; Fontenay M; Hellstrom-Lindberg E; Jansen JH; Dugas M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
Article: HAEMATOLOGICA. 2020;105(11):2516-2523
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
de Witte T; Malcovati L; Fenaux P; Bowen D; Symeonidis A; Mittelman M; Stauder R; Sanz G; Cermak J; Langemeijer S; Hellstrom-Lindberg E; Germing U; Holm MS; Madry K; Tatic A; Almeida AM; Savic A; Rogulj IM; Itzykson R; Hoeks M; Garelius HG; Culligan D; Kotsianidis I; Ades L; van de Loosdrecht AA; van Marrewijk C; Yu G; Crouch S; Smith A
Article: BLOOD ADVANCES. 2020;4(16):4029-4044
Guideline-based indicators for adult patients with myelodysplastic syndromes
Stojkov K; Silzle T; Stussi G; Schwappach D; Bernhard J; Bowen D; Cermak J; Dinmohamed AG; Eeltink C; Eggmann S; Fenaux P; Germing U; Haschke M; Hellstrom-Lindberg E; Heger M; van de Loosdrecht AA; Passweg J; Pfeilstoecker M; Platzbecker U; Malcovati L; de Almeida AM; Mittelman M; Morgenthaler C; Steensma DP; Santini V; Stauder R; Symeonidis A; Schaer S; Maddox C; de Witte T; Bohlius J; Bonadies N
Article: CANCER RESEARCH. 2020;80(12):2441-2450
Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine
Ohtani H; Orskov AD; Helbo AS; Gillberg L; Liu M; Zhou W; Ungerstedt J; Hellstrom-Lindberg E; Sun W; Liang G; Jones PA; Gronbaek K
Article: NATURE CELL BIOLOGY. 2020;22(5):526-533
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Martinez-Hoyer S; Deng Y; Parker J; Jiang J; Mo A; Docking TR; Gharaee N; Li J; Umlandt P; Fuller M; Jadersten M; Kulasekararaj A; Malcovati L; List AF; Hellstrom-Lindberg E; Platzbecker U; Karsan A
Article: HAEMATOLOGICA. 2020;105(3):632-639
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
de Swart L; Crouch S; Hoeks M; Smith A; Langemeijer S; Fenaux P; Symeonidis A; Cermak J; Hellstrom-Lindberg E; Stauder R; Sanz G; Mittelman M; Holm MS; Malcovati L; Madry K; Germing U; Tatic A; Savic A; Almeida AM; Gredelj-Simec N; Guerci-Bresler A; Beyne-Rauzy O; Culligan D; Kotsianidis I; Itzykson R; van Marrewijk C; Blijlevens N; Bowen D; de Witte T
Article: HAEMATOLOGICA. 2020;105(3):640-651
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Cermak J; Hellstrom-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Madry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Simec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; van de Loosdrecht A; van Marrewijk C; Droste J; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A
Article: NATURE. 2020;578(7793):82-93
Pan-cancer analysis of whole genomes
Campbell PJ; Getz G; Korbel JO; Stuart JM; Jennings JL; Stein LD; Perry MD; Nahal-Bose HK; Ouellette BFF; Li CH; Rheinbay E; Nielsen GP; Sgroi DC; Wu C-L; Faquin WC; Deshpande V; Boutros PC; Lazar AJ; Hoadley KA; Louis DN; Dursi LJ; Yung CK; Bailey MH; Saksena G; Raine KM; Buchhalter I; Kleinheinz K; Schlesner M; Zhang J; Wang W; Wheeler DA; Ding L; Simpson JT; O'Connor BD; Yakneen S; Ellrott K; Miyoshi N; Butler AP; Royo R; Shorser SI; Vazquez M; Rausch T; Tiao G; Waszak SM; Rodriguez-Martin B; Shringarpure S; Wu D-Y; Demidov GM; Delaneau O; Hayashi S; Imoto S; Habermann N; Segre AV; Garrison E; Cafferkey A; Alvarez EG; Maria Heredia-Genestar J; Muyas F; Drechsel O; Bruzos AL; Temes J; Zamora J; Baez-Ortega A; Kim H-L; Mashl RJ; Ye K; DiBiase A; Huang K-L; Letunic I; McLellan MD; Newhouse SJ; Shmaya T; Kumar S; Wedge DC; Wright MH; Yellapantula VD; Gerstein M; Khurana E; Marques-Bonet T; Navarro A; Bustamante CD; Siebert R; Nakagawa H; Easton DF; Ossowski S; Tubio JMC; De La Vega FM; Estivill X; Yuen D; Mihaiescu GL; Omberg L; Ferretti V; Sabarinathan R; Pich O; Gonzalez-Perez A; Weiner AT; Fittall MW; Demeulemeester J; Tarabichi M; Roberts ND; Van Loo P; Cortes-Ciriano I; Urban L; Park P; Bin Z; Pitkaenen E; Li Y; Saini N; Klimczak LJ; Weischenfeldt J; Sidiropoulos N; Alexandrov LB; Rabionet R; Escaramis G; Bosio M; Holik AZ; Susak H; Prasad A; Erkek S; Calabrese C; Raeder B; Harrington E; Mayes S; Turner D; Juul S; Roberts SA; Song L; Koster R; Mirabello L; Hua X; Tanskanen TJ; Tojo M; Chen J; Aaltonen LA; Ratsch G; Schwarz RF; Butte AJ; Brazma A; Chanock SJ; Chatterjee N; Stegle O; Harismendy O; Bova GS; Gordenin DA; Haan D; Sieverling L; Feuerbach L; Chalmers D; Joly Y; Knoppers B; Molnar-Gabor F; Phillips M; Thorogood A; Townend D; Goldman M; Fonseca NA; Xiang Q; Craft B; Pineiro-Yanez E; Munoz A; Petryszak R; Fullgrabe A; Al-Shahrour F; Keays M; Haussler D; Weinstein J; Huber W; Valencia A; Papatheodorou I; Zhu J; Fan Y; Torrents D; Bieg M; Chen K; Chong Z; Cibulskis K; Eils R; Fulton RS; Gelpi JL; Gonzalez S; Gut IG; Hach F; Heinold M; Hu T; Huang V; Hutter B; Jaeger N; Jung J; Kumar Y; Lalansingh C; Leshchiner I; Livitz D; Ma EZ; Maruvka YE; Milovanovic A; Nielsen MM; Paramasivam N; Pedersen JS; Puiggros M; Sahinalp SC; Sarrafi I; Stewart C; Stobbe MD; Wala JA; Wang J; Wendl M; Werner J; Wu Z; Xue H; Yamaguchi TN; Yellapantula V; Davis-Dusenbery BN; Grossman RL; Kim Y; Heinold MC; Hinton J; Jones DR; Menzies A; Stebbings L; Hess JM; Rosenberg M; Dunford AJ; Gupta M; Imielinski M; Meyerson M; Beroukhim R; Reimand J; Dhingra P; Favero F; Dentro S; Wintersinger J; Rudneva V; Park JW; Hong EP; Heo SG; Kahles A; Kjong-Van L; Soulette CM; Shiraishi Y; Liu F; He Y; Demircioglu D; Davidson NR; Greger L; Li S; Liu D; Stark SG; Zhang F; Amin SB; Bailey P; Chateigner A; Frenkel-Morgenstern M; Hou Y; Huska MR; Kilpinen H; Lamaze FC; Li C; Li X; Li X; Liu X; Marin MG; Markowski J; Nandi T; Ojesina AI; Pan-Hammarstrom Q; Park PJ; Pedamallu CS; Su H; Tan P; Teh BT; Wang J; Xiong H; Ye C; Yung C; Zhang X; Zheng L; Zhu S; Awadalla P; Creighton CJ; Wu K; Yang H; Goke J; Zhang Z; Brooks AN; Martincorena I; Rubio-Perez C; Juul M; Schumacher S; Shapira O; Tamborero D; Mularoni L; Hornshoj H; Deu-Pons J; Muinos F; Bertl J; Guo Q; Bazant W; Barrera E; Al-Sedairy ST; Aretz A; Bell C; Betancourt M; Buchholz C; Calvo F; Chomienne C; Dunn M; Edmonds S; Green E; Gupta S; Hutter CM; Jegalian K; Jones N; Lu Y; Nakagama H; Nettekoven G; Planko L; Scott D; Shibata T; Shimizu K; Stratton MR; Yugawa T; Tortora G; VijayRaghavan K; Zenklusen JC; Knoppers BM; Aminou B; Bartolome J; Boroevich KA; Boyce R; Buchanan A; Byrne NJ; Chen Z; Cho S; Choi W; Clapham P; Dow MT; Dursi LJ; Eils J; Farcas C; Fayzullaev N; Flicek P; Heath AP; Hofmann O; Hong JH; Hudson TJ; Huebschmann D; Ivkovic S; Jeon S-H; Jiao W; Kabbe R; Kerssemakers JNA; Kim H; Kim J; Koscher M; Koures A; Kovacevic M; Lawerenz C; Liu J; Mijalkovic S; Mijalkovic-Lazic AM; Miyano S; Nastic M; Nicholson J; Ocana D; Ohi K; Ohno-Machado L; Pihl TD; Prinz M; Radovic P; Short C; Sofia HJ; Spring J; Struck AJ; Tijanic N; Vicente D; Wang Z; Williams A; Woo Y; Wright AJ; Yang L; Hamilton MP; Johnson TA; Kahraman A; Kellis M; Polak P; Sallari R; Sinnott-Armstrong N; von Mering C; Beltran S; Gerhard DS; Gut M; Trotta J-R; Whalley JP; Niu B; Espiritu SMG; Gao S; Huang Y; Lalansingh CM; Teague JW; Wendl MC; Abascal F; Bader GD; Bandopadhayay P; Barenboim J; Brunak S; Fita JC; Chakravarty D; Chan CWY; Choi JK; Diamanti K; Fink JL; Frigola J; Gambacorti-Passerini C; Garsed DW; Haradhvala NJ; Harmanci AO; Helmy M; Herrmann C; Hobolth A; Hodzic E; Hong C; Isaev K; Izarzugaza JMG; Johnson R; Juul RI; Kim J; Kim JK; Komorowski J; Lanzos A; Larsson E; Lee D; Li S; Li X; Lin Z; Liu EM; Lochovsky L; Lou S; Madsen T; Marchal K; Fundichely AM; McGillivray PD; Meyerson W; Paczkowska M; Park K; Park K; Pons T; Pulido-Tamayo S; Reyes Salazar I; Reyna MA; Rubin MA; Salichos L; Sander C; Schumacher SE; Shackleton M; Shen C; Shrestha R; Shuai S; Tsunoda T; Umer HM; Uuskula-Reimand L; Verbeke LPC; Wadelius C; Wadi L; Warrell J; Wu G; Yu J; Zhang J; Zhang X; Zhang Y; Zhao Z; Zou L; Lawrence MS; Raphael BJ; Bailey PJ; Craft D; Goldman MJ; Aburatani H; Binder H; Dinh HQ; Heath SC; Hoffmann S; Imbusch CD; Kretzmer H; Laird PW; Martin-Subero JI; Nagae G; Shen H; Wang Q; Weichenhan D; Zhou W; Berman BP; Brors B; Plass C; Akdemir KC; Bowtell DDL; Burns KH; Busanovich J; Chan K; Dueso-Barroso A; Edwards PA; Etemadmoghadam D; Haber JE; Jones DTW; Ju YS; Kazanov MD; Koh Y; Kumar K; Lee EA; Lee JJ-K; Lynch AG; Macintyre G; Markowetz F; Navarro FCP; Pearson JV; Rippe K; Scully R; Villasante I; Waddell N; Yang L; Yao X; Yoon S-S; Zhang C-Z; Bergstrom EN; Boot A; Covington K; Fujimoto A; Huang MN; Islam SMA; McPherson JR; Morganella S; Mustonen V; Ng AWT; Prokopec SD; Vazquez-Garcia I; Wu Y; Yousif F; Yu W; Rozen SG; Rudneva VA; Shringarpure SS; Turner DJ; Xia T; Atwal G; Chang DK; Cooke SL; Faltas BM; Haider S; Kaiser VB; Karlic R; Kato M; Kubler K; Margolin A; Martin S; Nik-Zainal S; P'ng C; Semple CA; Smith J; Sun RX; Thai K; Wright DW; Yuan K; Biankin AV; Garraway L; Grimmond SM; Adams DJ; Anur P; Cao S; Christie EL; Cmero M; Cun Y; Dawson KJ; Dentro SC; Deshwar AG; Donmez N; Drews RM; Gerstung M; Ha G; Haase K; Jerman L; Ji Y; Jolly C; Lee J; Lee-Six H; Malikic S; Mitchell TJ; Morris QD; Oesper L; Peifer M; Peto M; Rosebrock D; Rubanova Y; Salcedo A; Sengupta S; Shi R; Shin SJ; Spiro O; Vembu S; Wintersinger JA; Yang T-P; Yu K; Zhu H; Spellman PT; Weinstein JN; Chen Y; Fujita M; Han L; Hasegawa T; Komura M; Li J; Mizuno S; Shimizu E; Wang Y; Xu Y; Yamaguchi R; Yang F; Yang Y; Yoon CJ; Yuan Y; Liang H; Alawi M; Borozan I; Brewer DS; Cooper CS; Desai N; Grundhoff A; Iskar M; Su X; Zapatka M; Lichter P; Alsop K; Bruxner TJC; Christ AN; Cordner SM; Cowin PA; Drapkin R; Fereday S; George J; Hamilton A; Holmes O; Hung JA; Kassahn KS; Kazakoff SH; Kennedy CJ; Leonard CR; Mileshkin L; Miller DK; Arnau GM; Mitchell C; Newell F; Nones K; Patch A-M; Quinn MC; Taylor DF; Thorne H; Traficante N; Vedururu R; Waddell NM; Waring PM; Wood S; Xu Q; DeFazio A; Anderson MJ; Antonello D; Barbour AP; Bassi C; Bersani S; Cataldo I; Chantrill LA; Chiew Y-E; Chou A; Cingarlini S; Cloonan N; Corbo V; Davi MV; Duthie FR; Gill AJ; Graham JS; Harliwong I; Jamieson NB; Johns AL; Kench JG; Landoni L; Lawlor RT; Mafficini A; Merrett ND; Miotto M; Musgrove EA; Nagrial AM; Oien KA; Pajic M; Pinese M; Robertson AJ; Rooman I; Rusev BC; Samra JS; Scardoni M; Scarlett CJ; Scarpa A; Sereni E; Sikora KO; Simbolo M; Taschuk ML; Toon CW; Vicentini C; Wu J; Zeps N; Behren A; Burke H; Cebon J; Dagg RA; De Paoli-Iseppi R; Dutton-Regester K; Field MA; Fitzgerald A; Hersey P; Jakrot V; Johansson PA; Kakavand H; Kefford RF; Lau LMS; Long GV; Pickett HA; Pritchard AL; Pupo GM; Saw RPM; Schramm S-J; Shang CA; Shang P; Spillane AJ; Stretch JR; Tembe V; Thompson JF; Vilain RE; Wilmott JS; Yang JY; Hayward NK; Mann GJ; Scolyer RA; Bartlett J; Bavi P; Chadwick DE; Chan-Seng-Yue M; Cleary S; Connor AA; Czajka K; Denroche RE; Dhani NC; Eagles J; Gallinger S; Grant RC; Hedley D; Hollingsworth MA; Jang GH; Johns J; Kalimuthu S; Liang S-B; Lungu I; Luo X; Mbabaali F; McPherson TA; Miller JK; Moore MJ; Notta F; Pasternack D; Petersen GM; Roehrl MHA; Sam M; Selander I; Serra S; Shahabi S; Thayer SP; Timms LE; Wilson GW; Wilson JM; Wouters BG; McPherson JD; Beck TA; Bhandari V; Collins CC; Fleshner NE; Fox NS; Fraser M; Heisler LE; Lalonde E; Livingstone J; Meng A; Sabelnykova VY; Shiah Y-J; Van Der Kwast T; Bristow RG; Ding S; Fan D; Li L; Nie Y; Xiao X; Xing R; Yang S; Yu Y; Zhou Y; Banks RE; Bourque G; Brennan P; Letourneau L; Riazalhosseini Y; Scelo G; Vasudev N; Viksna J; Lathrop M; Tost J; Ahn S-M; Aparicio S; Arnould L; Aure MR; Bhosle SG; Birney E; Borg A; Boyault S; Brinkman AB; Brock JE; Broeks A; Borresen-Dale A-L; Caldas C; Chin S-F; Davies H; Desmedt C; Dirix L; Dronov S; Ehinger A; Eyfjord JE; Fatima A; Foekens JA; Futreal PA; Garred O; Giri DD; Glodzik D; Grabau D; Hilmarsdottir H; Hooijer GK; Jacquemier J; Jang SJ; Jonasson JG; Jonkers J; Kim H-Y; King TA; Knappskog S; Kong G; Krishnamurthy S; Lakhani SR; Langerod A; Larsimont D; Lee HJ; Lee J-Y; Lee MTM; Lingjaerde OC; MacGrogan G; Martens JWM; O'Meara S; Pauporte I; Pinder S; Pivot X; Provenzano E; Purdie CA; Ramakrishna M; Ramakrishnan K; Reis-Filho J; Richardson AL; Ringner M; Rodriguez JB; Rodriguez-Gonzalez FG; Romieu G; Salgado R; Sauer T; Shepherd R; Sieuwerts AM; Simpson PT; Smid M; Sotiriou C; Span PN; Stefansson OA; Stenhouse A; Stunnenberg HG; Sweep F; Tan BKT; Thomas G; Thompson AM; Tommasi S; Treilleux I; Tutt A; Ueno NT; Van Laere S; Van den Eynden GG; Vermeulen P; Viari A; Vincent-Salomon A; Wong BH; Yates L; Zou X; van Deurzen CHM; van de Vijver MJ; van't Veer L; Ammerpohl O; Aukema S; Bergmann AK; Bernhart SH; Borkhardt A; Borst C; Burkhardt B; Claviez A; Goebler ME; Haake A; Haas S; Hansmann M; Hoell JI; Hummel M; Karsch D; Klapper W; Kneba M; Kreuz M; Kube D; Kueppers R; Lenze D; Loeffler M; Lopez C; Mantovani-Loeffler L; Moeller P; Ott G; Radlwimmer B; Richter J; Rohde M; Rosenstiel PC; Rosenwald A; Schilhabel MB; Schreiber S; Stadler PF; Staib P; Stilgenbauer S; Sungalee S; Szczepanowski M; Toprak UH; Truemper LHP; Wagener R; Zenz T; Hovestadt V; von Kalle C; Kool M; Korshunov A; Landgraf P; Lehrach H; Northcott PA; Pfister SM; Reifenberger G; Warnatz H-J; Wolf S; Yaspo M-L; Assenov Y; Gerhauser C; Minner S; Schlomm T; Simon R; Sauter G; Sueltmann H; Biswas NK; Maitra A; Majumder PP; Sarin R; Barbi S; Bonizzato G; Cantu C; Dei Tos AP; Fassan M; Grimaldi S; Luchini C; Malleo G; Marchegiani G; Milella M; Paiella S; Pea A; Pederzoli P; Ruzzenente A; Salvia R; Sperandio N; Arai Y; Hama N; Hiraoka N; Hosoda F; Nakamura H; Ojima H; Okusaka T; Totoki Y; Urushidate T; Fukayama M; Ishikawa S; Katai H; Katoh H; Komura D; Rokutan H; Saito-Adachi M; Suzuki A; Taniguchi H; Tatsuno K; Ushiku T; Yachida S; Yamamoto S; Aikata H; Arihiro K; Ariizumi S-I; Chayama K; Furuta M; Gotoh K; Hayami S; Hirano S; Kawakami Y; Maejima K; Nakamura T; Nakano K; Ohdan H; Sasaki-Oku A; Tanaka H; Ueno M; Yamamoto M; Yamaue H; Choo SP; Cutcutache I; Khuntikeo N; Ong CK; Pairojkul C; Popescu I; Ahn KS; Aymerich M; Lopez-Guillermo A; Lopez-Otin C; Puente XS; Campo E; Amary F; Baumhoer D; Behjati S; Bjerkehagen B; Futreal PA; Myklebost O; Pillay N; Tarpey P; Tirabosco R; Zaikova O; Flanagan AM; Boultwood J; Bowen DT; Cazzola M; Green AR; Hellstrom-Lindberg E; Malcovati L; Nangalia J; Papaemmanuil E; Vyas P; Ang Y; Barr H; Beardsmore D; Eldridge M; Gossage J; Grehan N; Hanna GB; Hayes SJ; Hupp TR; Khoo D; Lagergren J; Lovat LB; MacRae S; O'Donovan M; O'Neill JR; Parsons SL; Preston SR; Puig S; Roques T; Sanders G; Sothi S; Tavare S; Tucker O; Turkington R; Underwood TJ; Welch I; Fitzgerald RC; Berney DM; De Bono JS; Cahill D; Camacho N; Dennis NM; Dudderidge T; Edwards SE; Fisher C; Foster CS; Ghori M; Gill P; Gnanapragasam VJ; Gundem G; Hamdy FC; Hawkins S; Hazell S; Howat W; Isaacs WB; Karaszi K; Kay JD; Khoo V; Kote-Jarai Z; Kremeyer B; Kumar P; Lambert A; Leongamornlert DA; Livni N; Lu Y-J; Luxton HJ; Marsden L; Massie CE; Matthews L; Mayer E; McDermott U; Merson S; Neal DE; Ng A; Nicol D; Ogden C; Rowe EW; Shah NC; Thomas S; Thompson A; Verrill C; Visakorpi T; Warren AY; Whitaker HC; Zhang H; van As N; Eeles RA; Abeshouse A; Agrawal N; Akbani R; Al Ahmadie H; Albert M; Aldape K; Ally A; Appelbaum EL; Armenia J; Asa S; Auman JT; Balasundaram M; Balu S; Barnholtz-Sloan J; Bathe OF; Baylin SB; Benz C; Berchuck A; Berrios M; Bigner D; Birrer M; Bodenheimer T; Boice L; Bootwalla MS; Bosenberg M; Bowlby R; Boyd J; Broaddus RR; Brock M; Brooks D; Bullman S; Caesar-Johnson SJ; Carey TE; Carlsen R; Cerfolio R; Chandan VS; Chen H-W; Cherniack AD; Chien J; Cho J; Chuah E; Cibulskis C; Cope L; Cordes MG; Curley E; Czerniak B; Danilova L; Davis IJ; Defreitas T; Demchok JA; Dhalla N; Dhir R; Doddapaneni H; El-Naggar A; Felau I; Ferguson ML; Finocchiaro G; Fong KM; Frazer S; Friedman W; Fronick CC; Fulton LA; Gabriel SB; Gao J; Gehlenborg N; Gershenwald JE; Ghossein R; Giama NH; Gibbs RA; Gomez C; Govindan R; Hayes DN; Hegde AM; Heiman DI; Heins Z; Hepperla AJ; Holbrook A; Holt RA; Hoyle AP; Hruban RH; Hu J; Huang M; Huntsman D; Huse J; Donahue CAI; Ittmann M; Jayaseelan JC; Jefferys SR; Jones CD; Jones SJM; Juhl H; Kang KJ; Karlan B; Kasaian K; Kebebew E; Kim HK; Korchina V; Kundra R; Lai PH; Lander E; Le X; Lee D; Levine DA; Lewis L; Ley T; Li HI; Lin P; Linehan WM; Liu FF; Lu Y; Lype L; Ma Y; Maglinte DT; Mardis ER; Marks J; Marra MA; Matthew TJ; Mayo M; McCune K; Meier SR; Meng S; Mieczkowski PA; Mikkelsen T; Miller CA; Mills GB; Moore RA; Morrison C; Mose LE; Moser CD; Mungall AJ; Mungall K; Mutch D; Muzny DM; Myers J; Newton Y; Noble MS; O'Donnell P; O'Neill BP; Ochoa A; Park J-W; Parker JS; Pass H; Pastore A; Pennell NA; Perou CM; Petrelli N; Potapova O; Rader JS; Ramalingam S; Rathmell WK; Reuter V; Reynolds SM; Ringel M; Roach J; Roberts LR; Robertson AG; Sadeghi S; Saller C; Sanchez-Vega F; Schadendorf D; Schein JE; Schmidt HK; Schultz N; Seethala R; Senbabaoglu Y; Shelton T; Shi Y; Shih J; Shmulevich I; Shriver C; Signoretti S; Simons JV; Singer S; Sipahimalani P; Skelly TJ; McCune KS; Socci ND; Soloway MG; Sood AK; Tam A; Tan D; Tarnuzzer R; Thiessen N; Thompson RH; Thorne LB; Tsao M; Umbricht C; Van Den Berg DJ; Van Meir EG; Veluvolu U; Voet D; Wang L; Weinberger P; Weisenberger DJ; Wigle D; Wilkerson MD; Wilson RK; Winterhoff B; Wiznerowicz M; Wong T; Wong W; Xi L; Yau C; Zhang H; Zhang H; Zhang J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(2):140-151
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Diez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Goetze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso M-T; Mazure D; Vellenga E; Greenberg PL; Hellstrom-Lindberg E; Zeidan AM; Ades L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
Article: HEMASPHERE. 2019;3(6):e321
Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
Baliakas P; Tesi B; Wartiovaara-Kautto U; Stray-Pedersen A; Friis LS; Dybedal I; Hovland R; Jahnukainen K; Raaschou-Jensen K; Ljungman P; Rustad CF; Lautrup CK; Kilpivaara O; Kittang AO; Gronbaek K; Cammenga J; Hellstrom-Lindberg E; Andersen MK
Article: LEUKEMIA. 2019;33(7):1747-1758
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Ades L; Fenaux P; Shih L-Y; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellstrom-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tuechler H; Greenberg PL; Bejar R
Article: BLOOD. 2019;133(10):1020-1030
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
Platzbecker U; Fenaux P; Ades L; Giagounidis A; Santini V; van de Loosdrecht AA; Bowen D; de Witte T; Garcia-Manero G; Hellstrom-Lindberg E; Germing U; Stauder R; Malcovati L; Sekeres MA; Steensma DP; Gloaguen S
Article: BIOINFORMATICS. 2018;34(24):4205-4212
appreci8: a pipeline for precise variant calling integrating 8 tools
Sandmann S; Karimi M; de Graaf AO; Rohde C; Goellner S; Varghese J; Ernsting J; Walldin G; van der Reijden BA; Mueller-Tidow C; Malcovati L; Hellstroem-Lindberg E; Jansen JH; Dugas M
Article: BLOOD. 2018;132(12):1225-1240
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin A-C; Ho AD; Luft T; Hellstrom-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Article: BLOOD ADVANCES. 2018;2(16):2079-2089
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
Itzykson R; Crouch S; Travaglino E; Smith A; Symeonidis A; Hellstrom-Lindberg E; Sanz G; Cermak J; Stauder R; Elena C; Germing U; Mittelman M; Langemeijer S; Madry K; Tatic A; Holm MS; Almeida AM; Savic A; Simec NG; Luno E; Culligan D; Guerci-Bresler A; Malcovati L; van Marrewijk C; Bowen D; de Witte T; Fenaux P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register
Berggren DM; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: LEUKEMIA. 2018;32(6):1380-1392
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
Stauder R; Yu G; Koinig KA; Bagguley T; Fenaux P; Symeonidis A; Sanz G; Cermak J; Mittelman M; Hellstrom-Lindberg E; Langemeijer S; Holm MS; Madry K; Malcovati L; Tatic A; Germing U; Savic A; van Marrewijk C; Guerci-Bresler A; Luno E; Droste J; Efficace F; Smith A; Bowen D; de Witte T
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikstrom K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: LEUKEMIA RESEARCH. 2018;67:21-26
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
de Swart L; Smith A; Haase D; Fenaux P; Symeonidis A; Cermak J; Sanz G; Stauder R; Mittelman M; Hellstrom-Lindberg E; Malcovati L; Langemeijer S; Skov-Holm M; Madry K; Germing U; Almeida AM; Tatic A; Savic A; Simec NG; van Marrewijk C; Guerci-Bresler A; Sanhes L; Luno E; Culligan D; Beyne-Rauzy O; Burgstaller S; Blijlevens N; Bowen D; de Witte T
Article: BLOOD ADVANCES. 2018;2(5):534-548
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson A-S; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellstrom-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Article: HAEMATOLOGICA. 2018;103(1):69-79
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellstrom-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T
Article: CANCER IMMUNOLOGY RESEARCH. 2017;5(8):654-665
Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells
Liu LL; Beziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellstrom-Lindberg E; Soderhall S; Heyman M; Grander D; Malmberg K-J
Article: CELL REPORTS. 2017;20(3):572-585
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Unnikrishnan A; Papaemmanuil E; Beck D; Deshpande NP; Verma A; Kumari A; Woll PS; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj AG; Tobiasson M; Karimi M; Pellagatti A; Wilson SR; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; Wilkins MR; MacKenzie KL; Wong JWH; Campbell PJ; Pimanda JE
Article: ANNALS OF HEMATOLOGY. 2017;96(7):1105-1112
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
de Swart L; Smith A; MacKenzie M; Symeonidis A; Neukirchen J; Mikulenkova D; Vallespi T; Zini G; Paszkowska-Kowalewska M; Kruger A; Saft L; Fenaux P; Bowen D; Hellstrom-Lindberg E; Cermak J; Stauder R; Tatic A; Holm MS; Malcovati L; Madry K; Droste J; Blijlevens N; de Witte T; Germing U
Article: JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2017;10(1):131
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellstrom-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; del Canizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
Article: JOURNAL OF CLINICAL INVESTIGATION. 2017;127(6):2206-2221
The U2AF1^S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
Yip BH; Steeples V; Repapi E; Armstrong RN; Llorian M; Roy S; Shaw J; Dolatshad H; Taylor S; Verma A; Bartenstein M; Vyas P; Cross NCP; Malcovati L; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Smith CWJ; Pellagatti A; Boultwood J
Article: JOURNAL OF INTERNAL MEDICINE. 2017;281(3):284-299
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
Garelius HKG; Johnston WT; Smith AG; Park S; de Swart L; Fenaux P; Symeonidis A; Sanz G; Cermak J; Stauder R; Malcovati L; Mittelman M; van de Loosdrecht AA; van Marrewijk CJ; Bowen D; Crouch S; de Witte TJM; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2017;102(3):498-508
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jadersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SEW; Woll PS; Hellstrom-Lindberg E
Article: SCIENTIFIC REPORTS. 2017;7:43169
Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data
Sandmann S; de Graaf AO; Karimi M; van der Reijden BA; Hellstrom-Lindberg E; Jansen JH; Dugas M
Article: EXPERIMENTAL HEMATOLOGY. 2016;44(7):590-595.e1
GFI1^36N as a therapeutic and prognostic marker for myelodysplastic syndrome
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellstrom-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Moroy T; Duehrsen U; Maciejewski J; Khandanpour C
Article: ONCOTARGET. 2016;7(16):22103-22115
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2016;101(2):115-208
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert A; Balduini C; Brand A; Coiffier B; Cordonnier C; Doehner H; de Wit TD; Eichinger S; Fibbe W; Green T; de Haas F; Iolascon A; Jaffredo T; Rodeghiero F; Salles G; Schuringa JJ; Andre M; Andre-Schmutz I; Bacigalupo A; Bochud P-Y; den Boer M; Bonini C; Camaschella C; Cant A; Cappellini MD; Cazzola M; Lo Celso C; Dimopoulos M; Douay L; Dzierzak E; Einsele H; Ferreri A; De Franceschi L; Gaulard P; Gottgens B; Greinacher A; Gresele P; Gribben J; de Haan G; Hansen J-B; Hochhaus A; Kadir R; Kaveri S; Kouskoff V; Kuehne T; Kyrle P; Ljungman P; Maschmeyer G; Mendez-Ferrer S; Milsom M; Mummery C; Ossenkoppele G; Pecci A; Peyvandi F; Philipsen S; Reitsma P; Maria Ribera J; Risitano A; Rivella S; Ruf W; Schroeder T; Scully M; Socie G; Staal F; Stanworth S; Stauder R; Stilgenbauer S; Tamary H; Theilgaard-Monch K; Thein SL; Tilly H; Trneny M; Vainchenker W; Vannucchi AM; Viscoli C; Vrielink H; Zaaijer H; Zanella A; Zolla L; Zwaginga JJ; Martinez PA; van den Akker E; Allard S; Anagnou N; Andolfo I; Andrau J-C; Angelucci E; Anstee D; Aurer I; Avet-Loiseau H; Aydinok Y; Bakchoul T; Balduini A; Barcellini W; Baruch D; Baruchel A; Bayry J; Bento C; van den Berg A; Bernardi R; Bianchi P; Bigas A; Biondi A; Bohonek M; Bonnet D; Borchmann P; Borregaard N; Braekkan S; van den Brink M; Brodin E; Bullinger L; Buske C; Butzeck B; Cammenga J; Campo E; Carbone A; Cervantes F; Cesaro S; Charbord P; Claas F; Cohen H; Conard J; Coppo P; Vives Corrons J-L; da Costa L; Davi F; Delwel R; Dianzani I; Domanovic D; Donnelly P; Drnovsek TD; Dreyling M; Du M-Q; Dufour C; Durand C; Efremov D; Eleftheriou A; Elion J; Emonts M; Engelhardt M; Ezine S; Falkenburg F; Favier R; Federico M; Fenaux P; Fitzgibbon J; Flygare J; Foa R; Forrester L; Galacteros F; Garagiola I; Gardiner C; Garraud O; van Geet C; Geiger H; Geissler J; Germing U; Ghevaert C; Girelli D; Godeau B; Goekbuget N; Goldschmidt H; Goodeve A; Graf T; Graziadei G; Griesshammer M; Gruel Y; Guilhot F; von Gunten S; Gyssens I; Halter J; Harrison C; Harteveld C; Hellstrom-Lindberg E; Hermine O; Higgs D; Hillmen P; Hirsch H; Hoskin P; Huls G; Inati A; Johnson P; Kattamis A; Kiefel V; Kleanthous M; Klump H; Krause D; Hovinga JK; Lacaud G; Lacroix-Desmazes S; Landman-Parker J; LeGouill S; Lenz G; von Lilienfeld-Toal M; von Lindern M; Lopez-Guillermo A; Lopriore E; Lozano M; MacIntyre E; Makris M; Mannhalter C; Martens J; Mathas S; Matzdorff A; Medvinsky A; Menendez P; Migliaccio AR; Miharada K; Mikulska M; Minard V; Montalban C; de Montalembert M; Montserrat E; Morange P-E; Mountford J; Muckenthaler M; Mueller-Tidow C; Mumford A; Nadel B; Navarro J-T; el Nemer W; Noizat-Pirenne F; O'Mahony B; Oldenburg J; Olsson M; Oostendorp R; Palumbo A; Passamonti F; Patient R; de Latour RP; Pflumio F; Pierelli L; Piga A; Pollard D; Raaijmakers M; Radford J; Rambach R; Rao AK; Raslova H; Rebulla P; Rees D; Ribrag V; Rijneveld A; Rinalducci S; Robak T; Roberts I; Rodrigues C; Rosendaal F; Rosenwald A; Rule S; Russo R; Saglio G; Sanchez M; Scharf RE; Schlenke P; Semple J; Sierra J; So-Osman C; Manuel Soria J; Stamatopoulos K; Stegmayr B; Stunnenberg H; Swinkels D; Taborda Barata JP; Taghon T; Taher A; Terpos E; Thachil J; Tissot JD; Touw I; Toye A; Trappe R; Traverse-Glehen A; Unal S; Vaulont S; Viprakasit V; Vitolo U; van Wijk R; Wojtowicz A; Zeerleder S; Zieger B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;171(4):478-490
Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
Conte S; Katayama S; Vesterlund L; Karimi M; Dimitriou M; Jansson M; Mortera-Blanco T; Unneberg P; Papaemmanuil E; Sander B; Skoog T; Campbell P; Walfridsson J; Kere J; Hellstrom-Lindberg E
Article: ONCOTARGET. 2015;6(33):34178-34190
Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
Sohlberg E; Pfefferle A; Andersson S; Baumann BC; Hellstrom-Lindberg E; Malmberg K-J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;170(3):372-383
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellstroem-Lindberg E; Cermak J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Madry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luno E; Bowen D; de Witte T
Article: BLOOD. 2015;126(2):233-241
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jadersten M; Jansson M; Elena C; Galli A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungstrom V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Lindberg EH
Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2015;19(2):99-106
Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes
Ryblom H; Hast R; Hellstrom-Lindberg E; Winterling J; Johansson E
Article: NATURE COMMUNICATIONS. 2015;6:5901
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung M; Pellagatti A; Malcovati L; Giagounidis A; Della Porta MG; Jaedersten M; Dolatshad H; Verma A; Cross NCP; Vyas P; Killick S; Hellstroem-Lindberg E; Cazzola M; Papaemmanuil E; Campbell PJ; Boultwood J
Article: ANNALS OF HEMATOLOGY. 2015;94(1):23-34
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Oosterveld M; Suciu S; Muus P; Germing U; Delforge M; Belhabri A; Aul C; Selleslag D; Ferrant A; Marie J-P; Amadori S; Jehn U; Mandelli F; Hess U; Hellstrom-Lindberg E; Cakmak-Wollgast S; Vignetti M; Labar B; Willemze R; de Witte T
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;93(5):429-438
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Canizo C; Guerci-Bresler A; Nilsson L; Luebbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Goehring G; Fu T; Benettaib B; Hellstrom-Lindberg E; Fenaux P
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;93(5):439-445
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen S-E; Hellstrom-Lindberg E; Cherif H
Article: EUROPEAN RESPIRATORY JOURNAL. 2014;44(1):178-187
Lung transplantation in telomerase mutation carriers with pulmonary fibrosis
Silhan LL; Shah PD; Chambers DC; Snyder LD; Riise GC; Wagner CL; Hellstrom-Lindberg E; Orens JB; Mewton JF; Danoff SK; Arcasoy MO; Armanios M
Article: BMC MEDICAL GENETICS. 2014;15:68
A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome
Ueda Y; Calado RT; Norberg A; Kajigaya S; Roos G; Hellstrom-Lindberg E; Young NS
Article: CANCER CELL. 2014;25(6):794-808
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll PS; Kjallquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstrom-Lindberg E; Linnarsson S; Jacobsen SEW
Article: HAEMATOLOGICA. 2014;99(6):1041-1049
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Goehring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellstrom-Lindberg E
Article: BLOOD CANCER JOURNAL. 2014;4(3):e189
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
Tobiasson M; Dybedahl I; Holm MS; Karimi M; Brandefors L; Garelius H; Grovdal M; Hogh-Dufva I; Gronbaek K; Jansson M; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Mollgard L; Hellstrom-Lindberg E
Article: LEUKEMIA RESEARCH. 2014;38(2):258-262
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model
Fenaux P; Seymour JF; Santini V; Silverman L; Gore S; List A; Sanz G; Mufti GJ; Estey E; Swern AS; Beach CL; Hellstrom-Lindberg E
Article: BEST PRACTICE AND RESEARCH: CLINICAL HAEMATOLOGY. 2013;26(4):401-410
Erythropoiesis stimulating agents and other growth factors in low-risk MDS
Hellstrom-Lindberg EP; van de Loosdrecht A
Article: BLOOD. 2013;122(22):3616-3699
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil E; Gerstung M; Malcovati L; Tauro S; Gundem G; Van Loo P; Yoon CJ; Ellis P; Wedge DC; Pellagatti A; Shlien A; Groves MJ; Forbes SA; Raine K; Hinton J; Mudie LJ; McLaren S; Hardy C; Latimer C; Della Porta MG; O'Meara S; Ambaglio I; Galli A; Butler AP; Walldin G; Teague JW; Quek L; Sternberg A; Gambacorti-Passerini C; Cross NCP; Green AR; Boultwood J; Vyas P; Hellstrom-Lindberg E; Bowen D; Cazzola M; Stratton MR; Campbell PJ
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(28):3557-3564
Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes
Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Verma A; McDonald E-J; Killick S; Hellstrom-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(21):2662-2670
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
Article: HAEMATOLOGICA. 2013;98(7):1067-1072
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Gore SD; Fenaux P; Santini V; Bennett JM; Silverman LR; Seymour JF; Hellstrom-Lindberg E; Swern AS; Beach CL; List AF
Article: JOURNAL OF CLINICAL INVESTIGATION. 2013;123(5):2169-2182
Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions
Aziz A; Baxter EJ; Edwards C; Cheong CY; Ito M; Bench A; Kelley R; Silber Y; Beer PA; Chng K; Renfree MB; McEwen K; Gray D; Nangalia J; Mufti GJ; Hellstrom-Lindberg E; Kiladjian J-J; McMullin MF; Campbell PJ; Ferguson-Smith AC; Green AR
Article: LEUKEMIA. 2013;27(4):889-896
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts
Nikpour M; Scharenberg C; Liu A; Conte S; Karimi M; Mortera-Blanco T; Giai V; Fernandez-Mercado M; Papaemmanuil E; Hogstrand K; Jansson M; Vedin I; Wainscoat JS; Campbell P; Cazzola M; Boultwood J; Grandien A; Hellstrom-Lindberg E
Article: LEUKEMIA RESEARCH. 2013;37(3):266-273
Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
Saft L; Bjorklund E; Berg E; Hellstrom-Lindberg E; Porwit A
Article: BLOOD. 2012;119(1):206-216
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome inAML
Treppendahl MB; Qiu X; Sogaard A; Yang X; Nandrup-Bus C; Hother C; Andersen MK; Kjeldsen L; Mollgaard L; Hellstrom-Lindberg E; Jendholm J; Porse BT; Jones PA; Liang G; Gronbaek K
Article: BLOOD. 2011;118(24):6239-6246
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Galli A; Da Via MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellstrom-Lindberg E; Cazzola M
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2011;365(15):1384-1395
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil E; Cazzola M; Boultwood J; Malcovati L; Vyas P; Bowen D; Pellagatti A; Wainscoat JS; Hellstrom-Lindberg E; Gambacorti-Passerini C; Godfrey AL; Rapado I; Cvejic A; Rance R; McGee C; Ellis P; Mudie LJ; Stephens PJ; McLaren S; Massie CE; Tarpey PS; Varela I; Nik-Zainal S; Davies HR; Shlien A; Jones D; Raine K; Hinton J; Butler AP; Teague JW; Baxter EJ; Score J; Galli A; Della Porta MG; Travaglino E; Groves M; Tauro S; Munshi NC; Anderson KC; El-Naggar A; Fischer A; Mustonen V; Warren AJ; Cross NCP; Green AR; Futreal PA; Stratton MR; Campbell PJ
Article: BLOOD. 2011;118(14):3765-3776
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mufti G; Mittelman M; Muus P; Boekhorst PT; Sanz G; del Canizo C; Guerci-Bresler A; Nilsson L; Platzbecker U; Luebbert M; Quesnel B; Cazzola M; Ganser A; Bowen D; Schlegelberger B; Aul C; Knight R; Francis J; Fu T; Hellstrom-Lindberg E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;87(3):244-252
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
Nilsson-Ehle H; Birgegard G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engstrom LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2011;96(7):963-971
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Mollgard L; Saft L; Treppendahl MB; Dybedal I; Norgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jadersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Gronbaek K; Lindberg EH
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):1971-1979
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jaedersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Goehring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellstrom-Lindberg E; Mufti GJ
Article: BONE MARROW TRANSPLANTATION. 2011;46(5):719-726
Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT
Tobiasson M; Olsson R; Hellstrom-Lindberg E; Mattsson J
Article: HAEMATOLOGICA. 2011;96(2):319-322
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
Goehring G; Giagounidis A; Buesche G; Hofmann W; Kreipe HH; Fenaux P; Hellstrom-Lindberg E; Schlegelberger B
Article: HAEMATOLOGICA. 2010;95(10):1754-1761
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
de Witte T; Hagemeijer A; Suciu S; Belhabri A; Delforge M; Kobbe G; Selleslag D; Schouten HC; Ferrant A; Biersack H; Amadori S; Muus P; Jansen JH; Hellström-Lindberg E; Kovacsovics T; Wijermans P; Ossenkoppele G; Gratwohl A; Marie J-P; Willemze R
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2010;363(11):1025-1037
Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundstrom I; Strombeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Ryden T; Vyas P; Gohring G; Schlegelberger B; Johansson B; Hellstrom-Lindberg E; List A; Nilsson L; Jacobsen SEW
Article: LEUKEMIA. 2010;24(9):1607-1616
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34⁺ blasts in myelodysplastic syndrome
Carlsten M; Baumann BC; Simonsson M; Jadersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellstrom-Lindberg E; Malmberg K-J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2010;85(2):130-138
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
Santini V; Fenaux P; Mufti GJ; Hellstrom-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;150(3):293-302
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
Grovdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engstrom L-M; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;149(6):844-854
Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF
Nikpour M; Pellagatti A; Liu A; Karimi M; Malcovati L; Gogvadze V; Forsblom A-M; Wainscoat JS; Cazzola M; Zhivotovsky B; Grandien A; Boultwood J; Hellstrom-Lindberg E
Article: LEUKEMIA. 2010;24(5):932-941
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia
Deneberg S; Grovdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Doehner K; Paul C; Ekstrom TJ; Hellstrom-Lindberg E; Lehmann S
Article: LEUKEMIA. 2010;24(4):756-764
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Norbury CJ; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;149(2):244-249
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Fenaux P; Gattermann N; Seymour JF; Hellstroem-Lindberg E; Mufti GJ; Duehrsen U; Gore SD; Ramos F; Beyne-Rauzy O; List A; McKenzie D; Backstrom J; Beach CL
Article: ANNALS OF HEMATOLOGY. 2010;89(4):365-374
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
Goehring G; Giagounidis A; Buesche G; Kreipe HH; Zimmermann M; Hellstroem-Lindberg E; Aul C; Schlegelberger B
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(4):562-569
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux P; Mufti GJ; Hellstrom-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(3):437-444
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
Article: HAEMATOLOGICA. 2009;94(12):1762-1766
Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Jadersten M; Saft L; Pellagatti A; Goehring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellstrom-Lindberg E
Article: BLOOD. 2009;114(17):3538-3545
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Galli A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellstrom-Lindberg E; Cazzola M
Article: RHEUMATOLOGY. 2009;48(10):1222-1226
Myeloid leukaemia in systemic lupus erythematosus-a nested case-control study based on Swedish registers
Lofstrom B; Backlin C; Sundstrom C; Hellstrom-Lindberg E; Ekbom A; Lundberg IE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;146(1):86-90
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes
Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jadersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Article: THE LANCET ONCOLOGY. 2009;10(3):223-232
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux P; Mufti GJ; Hellstrom-Lindberg E; Santini V; Finelli C; Giagounidis A; Schoch R; Gattermann N; Sanz G; List A; Gore SD; Seymour JF; Bennett JM; Byrd J; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
Article: HAEMATOLOGICA. 2008;93(11):1712-1717
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
Mufti GJ; Bennett JM; Goasguen J; Bain BJ; Baumann I; Brunning R; Cazzola M; Fenaux P; Germing U; Hellstrom-Lindberg E; Jinnai I; Manabe A; Matsuda A; Niemeyer CM; Sanz G; Tomonaga M; Vallespi T; Yoshimi A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(21):3607-3613
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(1):57-64
Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal- and translation-related genes
Pellagatti A; Hellstrom-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
Article: PLOS ONE. 2008;3(4):e1970
The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
Boultwood J; Pellagatti A; Nikpour M; Pushkaran B; Fidler C; Cattan H; Littlewood TJ; Malcovati L; Della Porta MG; Jadersten M; Killick S; Giagounidis A; Bowen D; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS
Article: EXPERIMENTAL HEMATOLOGY. 2008;36(2):149-157
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells
Khan R; Schmidt-Mende J; Karim M; Gogvadze V; Hassan M; Ekstrom TJ; Zhivotovsky B; Hellstrom-Lindberg E
Article: SEMINARS IN HEMATOLOGY. 2008;45(1):14-22
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes
Hellstrom-Lindberg E; Malcovati L
Article: CLINICAL CANCER RESEARCH. 2007;13(23):7107-7112
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
Grovdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engstroem L-V; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;139(4):578-589
Gene expression profiling of CD34⁺ cells in patients with the 5q-syndrome
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jaedersten M; Killick S; Fidler C; Cazzola M; Hellstroem-Lindberg E; Wainscoat JS
Article: BLOOD. 2007;110(8):3005-3014
The molecular signature of MDS stem cells supports a stem-cell origin of 5q -: myelodysplastic syndromes
Nilsson L; Eden P; Olsson E; Mansson R; Astrand-Grundstrom I; Strombeck B; Theilgaard-Monch K; Anderson K; Hast R; Hellstroem-Lindberg E; Samuelsson J; Bergh G; Nerlov C; Johansson B; Sigvardsson M; Borg A; Jacobsen SEW
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(27):11406-11411
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Pellagatti A; Jaedersten M; Forsblom A-M; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Helistroem-Lindberg E
Article: ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 2007;23(1):129-131
Cobalt release from glazed earthenware:: Observations in a case of lead poisoning
Selden AI; Norberg C; Karlson-Stiber C; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2006;91(5):667-670
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
Broliden PA; Dahl I-M; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen J-M; Uggla B; Oberg G; Hellstrom-Lindberg E
Article: LEUKEMIA RESEARCH. 2006;30(3):247-253
Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes
Lundberg LG; Hellstrom-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Article: INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH. 2006;79(2):165-168
Lead poisoning from souvenir earthenware
Hellström-Lindberg E; Björklund A; Karlson-Stiber C; Harper P; Seldén AI
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(1):35-43
Pharmacodynamic study of 5-azacytidine in the P39 cell line
Khan R; Aggerholm A; Hokland P; Hassan M; Hellström-Lindberg E
Article: LEUKEMIA. 2006;20(1):42-47
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
Juliusson G; Billström R; Gruber A; Hellström-Linderg E; Höglund M; Karlsson K; Stockelberg D; Wahlin A; Åström M; Arnesson C; Brunell-Abrahamsson U; Carstensen J; Fredriksson E; Holmberg E; Nordenskjöld K; Wiklund F
Article: CELL DEATH AND DIFFERENTIATION. 2006;13(1):119-128
Early mitochondrial alterations in ATRA-induced cell death
Schmidt-Mende J; Gogvadze V; Hellström-Lindberg E; Zhivotovsky B
Article: CLINICAL CANCER RESEARCH. 2005;11(17):6291-6299
Antiapoptotic role of growth factors in the Myelodysplastic syndromes:: Concordance between in vitro and in vivo observations
Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hollström-Lindberg E
Article: BLOOD. 2005;106(1):247-253
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E
Article: SEMINARS IN HEMATOLOGY. 2005;42(2):S10-S13
Management of anemia associated with myelodysplastic syndrome
Hellström-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2005;35(1):37-43
Stem cell transplantation from identical twins in patients with myelodysplastic syndromes.
Kröger N; Brand R; van Biezen A; Bron D; Blaise D; Hellström-Lindberg E; Gahrton G; Powles R; Littlewood T; Chapuis B; Zander A; Koza V; Niederwieser D; de Witte T; Myelodysplastic Syndromes Subcommittee of the Chro
Article: HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM. 2005;:161-166
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
Hellström-Lindberg E
Article: HAEMATOLOGICA. 2004;89(12):1446-1453
Hypochromic red blood cells in low-risk myelodysplastic syndromes:: effects of treatment with hemopoietic growth factors
Ljung T; Bäck R; Hellström-Lindberg E
Article: BLOOD. 2004;103(9):3355-3361
Kostmann syndrome:: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells
Carlsson G; Aprikyan AAG; Tehranchi R; Dale DC; Porwit A; Hellström-Lindberg E; Palmblad J; Henter JI; Fadeel B
Article: BLOOD. 2004;103(9):3265-3270
The WHO classification of MDS does make a difference
Howe RB; Porwit-MacDonald A; Wanat R; Tehranchi R; Hellström-Lindberg E
Article: LEUKEMIA. 2003;17(9):1827-1833
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes:: better outcome in patients with less proliferative disease
Hast R; Hellström-Lindberg E; Ohm L; Björkholm M; Celsing F; Dahl JM; Dybedal I; Gahrton G; Lindberg G; Lerner R; Linder O; Löfvenberg E; Nilsson-Ehle H; Paul C; Samuelsson J; Tangen JM; Tidefelt U; Turesson I; Wahlin A; Wallvik J; Winquist I; Öberg G; Bernell P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2003;120(6):1037-1046
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IMS; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Öberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F
Article: BLOOD. 2003;101(3):1080-1086
Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors
Tehranchi R; Fadeel B; Forsblom AM; Christensson B; Samuelsson J; Zhivotovsky B; Hellstrom-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2002;30(3):141-147
The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo
Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Article: BLOOD. 2002;100(1):259-267
Involvement and functional impairment of the CD34⁺CD38^-Thy-1⁺ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8
Nilsson L; Åstrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SEW
Article: LEUKEMIA. 2001;15(8):1240-1247
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro
Hassan Z; Hassan M; Hellström-Lindberg E
Article: LEUKEMIA. 2001;15(5):742-751
Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts
Schmidt-Mende J; Tehranchi R; Forsblom AM; Joseph B; Christensson B; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(3):714-726
Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases
Lindberg EH; Schmidt-Mende J; Forsblom AM; Christensson B; Fadeel B; Zhivotovsky B
Article: LEUKEMIA RESEARCH. 2001;25(3):267-270
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD
Lindahl J; Kimby E; Björkstrand B; Christensson B; Hellström-Lindberg E
Article: LEUKEMIA RESEARCH. 2001;25(1):19-21
Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?
Bowen DT; Hellstrom-Lindberg E
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2000;245(1-2):91-94
Freezing induces artificial cleavage of apoptosis-related proteins in human bone marrow cells
Schmidt-Mende J; Hellström-Lindberg E; Joseph B; Zhivotovsky B
Article: BLOOD. 2000;96(6):2012-2021
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes:: evidence for involvement at the hematopoietic stem cell level
Nilsson L; Åstrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SEW
Article: EXPERIMENTAL HEMATOLOGY. 1999;27(8):1322-1329
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39
Hassan Z; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1999;105(4):966-973
Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes:: serum thrombopoietin levels and bone marrow morphology
Hellström-Lindberg E; Kanter-Lewensohn L; Nichol J; Öst Å
Article: LEUKEMIA. 1999;13(5):719-728
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells
Fadeel B; Hassan Z; Hellström-Lindberg E; Henter JI; Orrenius S; Zhivotovsky B
Article: BLOOD. 1998;92(1):68-75
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin:: Results from a randomized phase II study and long-term follow-up of 71 patients
Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Öberg G; Österborg A; Öst Å
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;99(2):344-351
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model
HellstromLindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Article: LEUKEMIA RESEARCH. 1997;21(5):415-425
Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin.
Hellström-Lindberg E; Kanter-Lewensohn L; Ost A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1996;56(3):124-129
Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Article: AMERICAN JOURNAL OF HEMATOLOGY. 1995;49(2):115-120
PERIPHERAL-BLOOD NEUTROPHIL MORPHOLOGY REFLECTS BONE-MARROW DYSPLASIA IN MYELODYSPLASTIC SYNDROMES
WIDELL S; HELLSTROMLINDBERG E; KOCK Y; LINDBERG M; OST A; HAST R
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1995;89(1):67-71
Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
Hellström-Lindberg E
Show more

All other publications

Review: THE LANCET HAEMATOLOGY. 2023;10(12):E994-E1005
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
Gurnari C; Robin M; Godley LA; Drozd-Sokolowska J; Wlodarski MW; Raj K; Onida F; Worel N; Ciceri F; Carbacioglu S; Kenyon M; Aljurf M; Bonfim C; Makishima H; Niemeyer C; Fenaux P; Zebisch A; Hamad N; Chalandon Y; Hellstrom-Lindberg E; Voso MT; Mecucci C; Duarte FB; Sebert M; de Fontbrune FS; Soulier J; Shimamura A; Lindsley RC; Maciejewski JP; Calado RT; Yakoub-Agha I; McLornan DP
Corrigendum: NATURE GENETICS. 2023;55(6):1076
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (vol 52, pg 331, 2020)
Cortes-Ciriano I; Lee JJ-K; Xi R; Jain D; Jung YL; Yang L; Gordenin D; Klimczak LJ; Zhang C-Z; Pellman DS; Park PJ
Letter: BLOOD ADVANCES. 2022;6(16):4705-4709
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
Hofman IJF; Mortera-Blanco T; Moura PL; Vestlund J; Larsson SV; Elvarsdottir EM; Walldin G; Tobiasson M; Sander B; Dimitriou M; Jacobsen S-EW; Woll PS; Jadersten M; Hellstrom-Lindberg E
Review: JOURNAL OF INTERNAL MEDICINE. 2022;292(2):262-277
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll PS; Yoshizato T; Hellstrom-Lindberg E; Fioretos T; Ebert BL; Jacobsen SEW
Letter: LEUKEMIA. 2022;36(5):1436-1439
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Rasmussen B; Gohring G; Bernard E; Nilsson L; Tobiasson M; Jadersten M; Garelius H; Dybedal I; Gronbaek K; Ejerblad E; Lorenz F; Flogegard M; Marcher CW; oster Fernstrom A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Norgaard JM; Saft L; Mollgard L; Hellstrom-Lindberg E
Letter: LEUKEMIA AND LYMPHOMA. 2022;63(3):755-758
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation
Jadersten M; Boriskina K; Lindholm C; Westrom S; Cavelier L; Hellstrom-Lindberg E; Mielke S; Tobiasson M
Editorial comment: NEUROLOGY: GENETICS. 2021;7(6):e628
Adult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant
Paucar M; Tesi B; Eshtad S; Eriksson C; Hashim F; Nilsson D; Pourhamidi K; Hellstrom-Lindberg E; Bryceson YT; Svenningsson P
Editorial comment: HEMASPHERE. 2021;5(9):e635
The EHA Research Roadmap: Malignant Myeloid Diseases
Doehner H; Malcovati L; Ossenkoppele GJ; Hochhaus A; Vannucchi AM; Bullinger L; Cervantes F; Craddock C; de Witte T; Doehner K; Dombret H; Fenaux P; Geissler J; Germing U; Guilhot F; Harrison C; Hellstrom-Lindberg E; Passamonti F; Sierra J; Skoda R; Wierzbowska A
Corrigendum: NATURE MEDICINE. 2021;27(5):927
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Corrigendum: NATURE MEDICINE. 2021;27(3):562
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Review: HAEMATOLOGICA. 2020;105(7):1765-1779
Myelodysplastic syndromes: moving towards personalized management
Hellstrom-Lindberg E; Tobiasson M; Greenberg P
Editorial comment: TRANSFUSION. 2019;59(6):1945-1952
A longer duration of red blood cell storage is associated with a lower hemoglobin increase after blood transfusion: a cohort study
Ryden J; Clements M; Hellstrom-Lindberg E; Hoglund P; Edgren G
Editorial comment: HEMASPHERE. 2018;2(3):e49
The European Hematology Curriculum: An Electronic Passport Promoting Professional Competence and Mobility
Almeida AM; Ar C; Hellstrom-Lindberg E; Hollegien WWG; Navarro JT; Saris MT; Wondergem MJ; Toh CH
Review: CANCER RESEARCH. 2017;77(6):1250-1260
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
Leroy B; Ballinger ML; Baran-Marszak F; Bond GL; Braithwaite A; Concin N; Donehower LA; El-Deiry WS; Fenaux P; Gaidano G; Langerod A; Hellstrom-Lindberg E; Iggo R; Lehmann-Che J; Mai PL; Malkin D; Moll UM; Myers JN; Nichols KE; Pospisilova S; Ashton-Prolla P; Rossi D; Savage SA; Strong LC; Tonin PN; Zeillinger R; Zenz T; Fraumeni JFJ; Taschner PEM; Hainaut P; Soussi T
Letter: HAEMATOLOGICA. 2015;100(6):e223-e225
High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia
Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellstrom-Lindberg E
Editorial comment: HAEMATOLOGICA. 2014;99(3):404-408
Survey of professional competence in hematology in Europe.
Lindberg EH; Almeida A; Enoksson F; de Wit TD; Strivens J; Naeve A; Toh C-H
Letter: LEUKEMIA. 2014;28(2):411-413
Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation
Grovdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellstrom-Lindberg E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(4):610-611
Cardiac iron overload assessed by T2*magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients
Bowen DT; Hellstrom-Lindberg E; Steensma DP
Review: BLOOD. 2013;122(17):2943-2964
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Malcovati L; Hellstrom-Lindberg E; Bowen D; Ades L; Cermak J; del Canizo C; Della Porta MG; Fenaux P; Gattermann N; Germing U; Jansen JH; Mittelman M; Mufti G; Platzbecker U; Sanz GF; Selleslag D; Skov-Holm M; Stauder R; Symeonidis A; van de Loosdrecht AA; de Witte T; Cazzola M
Editorial comment: HAEMATOLOGICA. 2013;98(7):1000-1002
A European strategy for targeted education in hematology
Strivens J; Hellstrom-Lindberg E; Bjerrum OW; Toh C-H
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2013;90(3):259-260
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q
Treppendahl MB; Mollgard L; Hellstrom-Lindberg E; Cloos P; Gronbaek K
Review: LEUKEMIA AND LYMPHOMA. 2013;54(3):472-475
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
van de Loosdrecht AA; Ireland R; Kern W; Della Porta MG; Alhan C; Balleisen JS; Bettelheim P; Bowen DT; Burbury K; Eidenschink L; Cazzola M; Chu SSC; Cullen M; Cutler JA; Drager AM; Feuillard J; Fenaux P; Font P; Germing U; Haase D; Hellstrom-Lindberg E; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Nikolova V; Ogata K; Oelschlaegel U; Orfao A; Ossenkoppele GJ; Porwit A; Platzbecker U; Preijers F; Psarra K; Richards SJ; Subira D; Seymour JF; Tindell V; Vallespi T; Valent P; van der Velden VHJ; Wells DA; de Witte TM; Zettl F; Bene MC; Westers TM
Editorial comment: HAEMATOLOGICA. 2012;97(12):1776-1778
H-Net, the European Network for Harmonization of Training in Hematology, and its policy
de Wit TD; Hellstrom-Lindberg E; Jaeger U; Evans-Jones G; Smand C
Letter: LEUKEMIA AND LYMPHOMA. 2012;53(8):1613-1616
Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome
Fleming S; Hellstrom-Lindberg E; Burbury K; Seymour JF
Editorial comment: HAEMATOLOGICA. 2012;97(5):636-637
Towards a joint definition of European hematology
Ossenkoppele G; Evans-Jones G; Jaeger U; Hellstrom-Lindberg E
Letter: LEUKEMIA. 2012;26(2):356-358
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
Goehring G; Lange K; Hofmann W; Nielsen KV; Hellstrom-Lindberg E; Roy L; Morgan M; Kreipe H; Buesche G; Giagounidis A; Schlegelberger B
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2011;155(2):272-274
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Vyas P; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Published conference paper: CANCER. 2011;117(12):2697-2702
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Silverman LR; Fenaux P; Mufti GJ; Santini V; Hellstrom-Lindberg E; Gattermann N; Sanz G; List AF; Gore SD; Seymour JF
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2010;76(3):218-227
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
Seymour JF; Fenaux P; Silverman LR; Mufti GJ; Hellstrom-Lindberg E; Santini V; List AF; Gore SD; Backstrom J; McKenzie D; Beach CL
Review: LEUKEMIA RESEARCH. 2010;34(11):1410-1416
Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
Fenaux P; Bowen D; Gattermann N; Hellstrom-Lindberg E; Hofmann W-K; Pfeilstoecker M; Sanz G; Santini V
Editorial comment: LEUKEMIA AND LYMPHOMA. 2010;51(7):1155-1156
Erythropoiesis-stimulating agents in myelodysplastic syndromes
Hellstrom-Lindberg E
Review: EXPERIMENTAL CELL RESEARCH. 2010;316(8):1390-1396
New clues to the molecular pathogenesis of myelodysplastic syndromes
Jadersten M; Helistrom-Lindberg E
Letter: LEUKEMIA. 2010;24(5):1062-1065
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia
Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS
Review: BLOOD REVIEWS. 2010;24(2):83-90
Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
Hellstrom-Lindberg E
Letter: BLOOD. 2010;115(3):749-750
Factors considered in the 2008 WHO classification of myeloid neoplasms and acute leukemias Response
Vardiman J; Thiele J; Arber DA; Brunning R; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellstrom-Lindberg E; Tefferi A; Bloomfield CD
Meeting abstract: BLOOD. 2009;114(22):306
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Published conference paper: BLOOD. 2009;114(5):937-951
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellstrom-Lindberg E; Tefferi A; Bloomfield CD
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S133-S134
Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
Silverman L; Fenaux P; Santini V; Seymour J; Mufti G; Hellstrom-Lindberg E; Giagounidis A; Sanz G; Bennett J; Backstrom J; McKenzie D; Beach C
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S133
Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)
Santini V; Silverman L; Seymour J; Fenaux P; Mufti G; Hellstrom-Lindberg E; Sanz G; Finelli C; Backstom J; McKenzie D; Beach C
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S66-S67
European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes
Bowen D; Droste J; Smith A; Fenaux P; Symeonidis A; Sanz G; Hellstrom-Lindberg E; Cermak J; Gologan R; Germing U; Stauder R; Malcovati L; de Witte T
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S26-S27
Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide
Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S55
Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Nikpour M; Pellagatti A; Liu A; Karimi M; Malcovati L; Forsblom A-M; Gogvadze V; Wainscoat JS; Cazzola M; Zhivotovsky B; Grandien A; Boultwood J; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S48
Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions
Scharenberg C; Jadersten M; Palmquist J; Forsblom L; Jansson M; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S39
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
Jadersten M; Saft L; Garelius H; Hast R; Nilsson L; Samuelsson J; Porwit A; Hellstrom-Lindberg E
Review: JOURNAL OF INTERNAL MEDICINE. 2009;265(3):307-328
Myelodysplastic syndromes: biology and treatment
Jadersten M; Hellstrom-Lindberg E
Editorial comment: THE LANCET ONCOLOGY. 2008;9(5):412-413
Erythropoietins should be used according to guidelines
Aapro MS; Birgegard G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellstrom-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Review: BLOOD REVIEWS. 2008;22(2):75-91
Supportive care, growth factors, and new therapies in myelodysplastic syndromes
Hellstrom-Lindberg E; Malcovati L
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(7):1180
Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application
Bowen DT; Fenaux P; Hellstrom-Lindberg E; de Witte T
Review: HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM. 2008;:52-59
The role of JAK2 mutations in RARS and other MDS.
Hellström-Lindberg E; Cazzola M
Meeting abstract: BLOOD. 2007;110(11):251A
Maintenance treatment with azacytidine for patients with high risk Myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy
Grovdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engstrom L-M; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellstrom-Lindberg E
Meeting abstract: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2007;64:S16
Managing myelodysplastic syndromes in the frail elderly
Hellstroem-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S17
Treatment of myelodysplastic syndromes with erythropoietin and G-CSF
Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S35
Expression profiling of CD34+cells in patients with myelodysplastic syndromes:: differences between early and advanced cases and analysis of apoptosis-related genes
Pellagatti A; Cazzola M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cattan H; Bowen D; Aul C; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S113-S114
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need
Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit-MacDonald A; Cazzola M; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S62-S63
Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells
Khan R; Schmidt-Mende J; Karimi M; Forsblom A-M; Gogvadze V; Hassan M; Ekstrom TJ; Zhivotovsky B; Hellstrom-Lindberg E
Meeting abstract: BLOOD. 2005;106(11):175B
A distinct molecular signature of purified cancer stem cells:: Evidence for a hematopoietic stem cell origin of the 5q-syndrome
Nilsson L; Edén P; Olsson E; Månsson R; Åstrand-Grundström I; Strömbeck B; Tehranchi R; Theilgaard-Mönch K; Hast R; Hellström-Lindberg E; Samuelsson J; Bergh G; Johansson B; Sigvardsson M; Borg A; Jacobsen SEW
Review: CURRENT DRUG TARGETS. 2005;6(6):713-725
Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
Lindberg EH
Published conference paper: BLOOD. 2005;106(3):803-811
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten M; Montgomery SM; Dybedal I; Porwit-MacDonald A; Hellström-Lindberg E
Review: CURRENT HEMATOLOGY REPORTS. 2003;2(2):122-129
Approach to anemia associated with myelodysplastic syndromes.
Hellström-Lindberg E
Other: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2002;75(2):209-212
Sixth International Symposium on Myelodysplastic Syndromes, Stockholm, June 14-17, 2001.
Hellström-Lindberg E
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(17):3791-3792
Classifying chronic myelomonocytic leukemia - In Reply
Greenberg P; Anderson J; Estey E; Fenaux P; Hamblin T; Hellstrom-Lindberg E; List A; Ohyashiki K; Sanz G; Sanz M
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2000;18(19):3447-3449
Problematic WHO reclassification of myelodysplastic syndromes
Greenberg P; Anderson J; de Witte T; Estey E; Fenaux P; Gupta P; Hamblin T; Hellstrom-Lindberg E; List A; Mufti G; Neuwirtova R; Ohyashiki K; Oscier D; Sanz G; Sanz M; Willman C
Review: INTERNATIONAL JOURNAL OF HEMATOLOGY. 1999;70(3):141-154
Treatment of adult myelodysplastic syndromes
Hellström-Lindberg E
Letter: THE LANCET. 1999;353(9155):846
Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation
Nordesjö-Haglund G; Lönnqvist B; Lindberg G; Hellstrôm-Lindberg E
Review: HAEMATOLOGICA. 1998;83(10):910-935
A patient-oriented approach to treatment of myelodysplastic syndromes.
Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 1995;91(1):257-258
RECOMBINANT ERYTHROPOIETIN FOR MYELODYSPLASTIC SYNDROMES
HELLSTROMLINDBERG E
Show more

Employments

Professor/Senior Physician, Department of Medicine, Huddinge, Karolinska Institutet, 2009-

Supervisor

Anna Tranberg

About me

Research

Selected publications

Articles

All other publications

Employments

Supervisor

News from KI

Events from KI